Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 45.55% is 319% above its 5-year average of -20.78%, near the high end of its 5-year range (-212.76%–46.89%).
1346.03% above its 12-month average of 3.15%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 17.99%.
RETURN ON ASSETS (ROA)
45.55%
RETURN ON ASSETS (ROA) AVG TTM
3.15%
RETURN ON ASSETS (ROA) AVG 3Y
-47.64%
RETURN ON ASSETS (ROA) AVG 5Y
-20.78%
RETURN ON ASSETS (ROA) AVG 10Y
-23.48%
RETURN ON ASSETS (ROA) AVG 15Y
-18.69%
RETURN ON ASSETS (ROA) AVG 20Y
-21.12%
CURRENT VS TTM AVG
+1346.03%
CURRENT VS 3Y AVG
+195.62%
CURRENT VS 5Y AVG
+319.22%
CURRENT VS 10Y AVG
+294.03%
CURRENT VS 15Y AVG
+343.74%
CURRENT VS 20Y AVG
+315.70%
SECTOR MEDIAN · HEALTHCARE
-29.10%
median of 631 covered companies
CURRENT VS SECTOR MEDIAN
+256.53%
vs the sector median at left
Ironwood Pharmaceuticals, Inc.
Market Cap
$597.83M
Return on Assets (ROA)
45.55%
TTM Avg
3.15%
3Y Avg
-47.64%
5Y Avg
-20.78%
Market Cap
$595.69M
Return on Assets (ROA)
-41.48%
TTM Avg
-39.59%
3Y Avg
-35.47%
5Y Avg
-52.36%
Market Cap
$600.96M
Return on Assets (ROA)
-7.75%
TTM Avg
-4.25%
3Y Avg
-2.93%
5Y Avg
9.76%
Market Cap
$609.86M
Return on Assets (ROA)
-13.75%
TTM Avg
-12.94%
3Y Avg
-23.44%
5Y Avg
-17.36%
Market Cap
$582.66M
Return on Assets (ROA)
-7.77%
TTM Avg
-7.89%
3Y Avg
-5.07%
5Y Avg
-5.95%
Market Cap
$568.37M
Return on Assets (ROA)
-59.22%
TTM Avg
-47.88%
3Y Avg
-51.20%
5Y Avg
-67.88%
Market Cap
$564.07M
Return on Assets (ROA)
20.70%
TTM Avg
2.32%
3Y Avg
-24.93%
5Y Avg
-30.88%
Market Cap
$562.43M
Return on Assets (ROA)
-37.16%
TTM Avg
-32.95%
3Y Avg
-32.95%
5Y Avg
-32.95%
Market Cap
$561.46M
Return on Assets (ROA)
-20.89%
TTM Avg
7.49%
3Y Avg
-5.84%
5Y Avg
-12.60%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ironwood Pharmaceuticals, Inc. (IRWD) | $597.83M | 45.55% | 3.15% | -47.64% | -20.78% |
| ArriVent BioPharma, Inc. (AVBP)vs › | $595.69M | -41.48% | -39.59% | -35.47% | -52.36% |
| Fulgent Genetics, Inc. (FLGT)vs › | $600.96M | -7.75% | -4.25% | -2.93% | 9.76% |
| AngioDynamics, Inc. (ANGO)vs › | $609.86M | -13.75% | -12.94% | -23.44% | -17.36% |
| OrthoPediatrics Corp. (KIDS)vs › | $582.66M | -7.77% | -7.89% | -5.07% | -5.95% |
| Aquestive Therapeutics, Inc. (AQST)vs › | $568.37M | -59.22% | -47.88% | -51.20% | -67.88% |
| CorMedix Inc. (CRMD)vs › | $564.07M | 20.70% | 2.32% | -24.93% | -30.88% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $562.43M | -37.16% | -32.95% | -32.95% | -32.95% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $561.46M | -20.89% | 7.49% | -5.84% | -12.60% |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
ROA
45.5%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 6.05% |
| 2024-12-31 | 0.25% |
| 2023-12-31 | -212.76% |
| 2022-12-31 | 15.91% |
| 2021-12-31 | 46.89% |
| 2020-12-31 | 18.99% |
| 2019-12-31 | 5.34% |
| 2018-12-31 | -85.04% |
| 2017-12-31 | -19.31% |
| 2016-12-31 | -11.51% |
| 2015-12-31 | -23.04% |
| 2014-12-31 | -56.85% |
| 2013-12-31 | -97.80% |
| 2012-12-31 | -31.59% |
| 2011-12-31 | -31.03% |
| 2010-12-31 | -17.58% |
| 2009-12-31 | -43.82% |
| 2008-12-31 | -38.28% |
| 2007-12-31 | -38.81% |
| 2006-12-31 | 0.00% |
